IGC Pharma, Inc.
IGCNYSE
$0.26
↑ +1.4%Jul 17 close · end-of-day
Price
1Y↓ -22.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$25.5M
Enterprise Value
$25.3M
P/E
—
P/S
21.5
P/B
4.2
EV/EBITDA
—
PEG
—
FCF Yield
-23.5%
Dividend Yield
—
Revenue (TTM)
$1.2M
Net Income (TTM)
-$6.5M
Free Cash Flow (TTM)
-$6.0M
Gross Margin
29.7%
Operating Margin
-860.3%
Net Margin
—
ROE
—
ROIC
-136.9%
Debt / Equity
—
Net Cash
$235,000.00
Return 1Y
-23.3%
Company profile
IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.
- CEO
- Ram Mukunda
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 61
- Headquarters
- Maryland
- Website
- igcpharma.com
Earnings
IGC Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$317,000.00↓ -3.9%
Diluted EPS-$0.020.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $898,000.00 | $397,000.00 | $911,000.00 | $1.3M | $1.3M |
| Gross profit | $113,000.00 | $194,000.00 | $442,000.00 | $733,000.00 | $619,000.00 |
| Operating income | -$8.7M | -$15.4M | -$11.6M | -$9.8M | -$7.4M |
| Net income | -$8.8M | -$15.0M | -$11.5M | -$13.0M | -$7.1M |
| Diluted EPS | — | — | — | -$0.22 | -$0.09 |
| Operating cash flow | -$10.8M | -$7.5M | -$7.0M | -$5.2M | -$4.8M |
| Free cash flow | -$12.3M | -$7.7M | -$7.4M | -$5.3M | -$4.9M |
| Gross margin | 12.6% | 48.9% | 48.5% | 54.5% | 48.7% |
| Operating margin | -971.5% | -3886.1% | -1270.1% | -728.5% | -585.8% |
| Net margin | -981.2% | -3782.4% | -1263.0% | -966.5% | -560.3% |
| Line item | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $272,000.00 | $412,000.00 | $257,000.00 | $330,000.00 | $328,000.00 | $191,000.00 | $350,000.00 | $317,000.00 |
| Gross profit | $163,000.00 | $198,000.00 | $104,000.00 | $154,000.00 | $154,000.00 | $99,000.00 | $44,000.00 | $55,000.00 |
| Operating income | -$2.4M | -$1.8M | -$1.9M | -$1.4M | -$1.9M | -$2.9M | -$2.9M | -$2.5M |
| Net income | -$2.4M | -$1.7M | -$1.8M | -$1.2M | -$1.6M | -$1.8M | -$726,000.00 | -$2.4M |
| Diluted EPS | -$0.03 | -$0.02 | -$0.02 | -$0.02 | -$0.02 | -$0.02 | -$0.01 | -$0.02 |
| Operating cash flow | -$1.8M | -$996,000.00 | -$1.3M | -$730,000.00 | -$1.4M | -$2.1M | -$1.2M | -$1.2M |
| Free cash flow | -$1.8M | -$1.0M | -$1.3M | -$748,000.00 | -$1.4M | -$2.1M | -$1.2M | -$1.2M |
| Gross margin | 59.9% | 48.1% | 40.5% | 46.7% | 47.0% | 51.8% | 12.6% | 17.4% |
| Operating margin | -880.9% | -427.2% | -730.7% | -428.2% | -580.8% | -1517.8% | -840.3% | -775.4% |
| Net margin | -874.3% | -416.7% | -711.7% | -363.0% | -487.5% | -953.4% | -207.4% | -757.7% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | MUKUNDA RAM· CEO | Award | 2,226,475 | $0.27 | $601,148.25 | filing |
| 2026-06-30 | GRIMALDI CLAUDIA· PFO | Award | 2,048,378 | $0.27 | $553,062.06 | filing |
| 2026-04-01 | MUKUNDA RAM· CEO | Option exercise | 323,077 | $0.26 | $84,000.02 | filing |
| 2026-04-01 | GRIMALDI CLAUDIA· PFO | Option exercise | 138,462 | $0.26 | $36,000.12 | filing |
| 2026-04-01 | MUKUNDA RAM· CEO | Option exercise | 16,667 | $0.00 | $0.00 | filing |
| 2026-04-01 | MUKUNDA RAM· CEO | Option exercise | 33,332 | $0.00 | $0.00 | filing |
| 2026-04-01 | Moran James P | Option exercise | 50,000 | $0.00 | $0.00 | filing |
| 2026-04-01 | GRIMALDI CLAUDIA· PFO | Option exercise | 100,000 | $0.00 | $0.00 | filing |
| 2026-04-01 | Moran James P | Option exercise | 80,000 | $0.00 | $0.00 | filing |
| 2026-04-01 | PRINS RICHARD K | Option exercise | 100,000 | $0.00 | $0.00 | filing |
| 2026-04-01 | PRINS RICHARD K | Option exercise | 70,000 | $0.00 | $0.00 | filing |
| 2026-04-01 | MUKUNDA RAM· CEO | Option exercise | 333,333 | $0.00 | $0.00 | filing |
| 2026-02-03 | MUKUNDA RAM· CEO | Option exercise | 50,000 | $0.00 | $0.00 | filing |
| 2026-01-19 | PRINS RICHARD K | Option exercise | 100,000 | $0.00 | $0.00 | filing |
| 2025-10-17 | GRIMALDI CLAUDIA· PFO | Gift | 50,000 | $0.00 | $0.00 | filing |
| 2025-10-17 | MUKUNDA RAM· CEO | Gift | 100,000 | $0.00 | $0.00 | filing |
Latest 16 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.